Evidence map›Paper›PMID 42879771›Full record

ArticleJMIR research protocols2026

Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study.

Kevin Cowart, Raechel T White, Nicholas W Carris, Benedicta O Ansong, Alyssa Hinden, Gwendolyn Clayton, John Petrilli, Eric Coris

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07529366 (Redefining Prediabetes Care), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07529366 recruitingnot on this map

Redefining Prediabetes Care: Pharmacist-Led Continuous Glucose Monitoring to Drive Lifestyle Change

TypeobservationalSponsorUniversity of South FloridaRan2026 to 2027Enrolled40ConditionsPrediabetesArmsDexcom Stelo CGM
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kevin CowartDepartment of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, United States.ORCID https://orcid.org/0000-0002-6880-1600
Raechel T WhiteDepartment of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, United States.ORCID https://orcid.org/0000-0002-5929-5590
Nicholas W CarrisDepartment of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, United States.ORCID https://orcid.org/0000-0001-8904-5034
Benedicta O AnsongDepartment of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, United States.ORCID https://orcid.org/0009-0000-2653-1414
Alyssa HindenDepartment of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, United States.ORCID https://orcid.org/0009-0008-7425-3744
Gwendolyn ClaytonDepartment of Family Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, United States.ORCID https://orcid.org/0009-0009-2958-7785
John PetrilliDepartment of Family Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, United States.ORCID https://orcid.org/0000-0002-8833-486X
Eric CorisDepartment of Family Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, United States.ORCID https://orcid.org/0000-0001-8484-7345

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrediabetes represents a critical intervention window to reduce progression to type 2 diabetes. The current standard of care for treatment of prediabetes is weight loss and lifestyle modification, which are both highly effective, although limited by real-world adherence. It is well recognized that continuous glucose monitoring (CGM) improves glycemic and behavioral outcomes in people with diabetes, although outcomes among people with prediabetes are not well described.

objectiveThe aim of this study is to evaluate the impact of pharmacist-led CGM on glycemic control and health-related behaviors in adults with prediabetes.

methodsThis study includes a prospective pharmacist-led CGM cohort and a matched retrospective usual-care cohort. Adults aged 18 to 70 years with prediabetes (hemoglobin A

resultsThis study was funded in 2026. Recruitment is ongoing, and no participants had been enrolled at the time of writing. The planned sample size is 40 participants: 20 prospective CGM participants and 20 retrospective controls. Outcome data are not yet available. The study is expected to be completed in July 2027, and the results are anticipated to be disseminated in December 2027.

conclusionsThis study seeks to evaluate the glycemic impact, behavior change, and safety of pharmacist-led CGM for prediabetes in primary care.

trial registrationClinicalTrials.gov NCT07529366; https://tinyurl.com/33bv7u8c. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/105275.

Indexed as

Continuous Glucose MonitoringPharmacistsPrediabetic StateAdolescentAdultAgedBlood GlucoseDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansMaleMiddle AgedObservational Studies as TopicProspective StudiesYoung AdultBlood GlucoseGlycated Hemoglobincontinuous glucose monitoringdiabetes preventionhealth behaviorpharmacistprediabetesprimary care

Identifiers

PMID42879771
PMCPMC13720402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.